nodes	percent_of_prediction	percent_of_DWPC	metapath
Triazolam—CYP3A7—Paclitaxel—ovarian cancer	0.0759	0.131	CbGbCtD
Triazolam—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.0759	0.131	CbGbCtD
Triazolam—CYP3A5—Paclitaxel—ovarian cancer	0.0569	0.0983	CbGbCtD
Triazolam—CYP3A7—Docetaxel—ovarian cancer	0.0549	0.0947	CbGbCtD
Triazolam—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.0549	0.0947	CbGbCtD
Triazolam—CYP2C8—Paclitaxel—ovarian cancer	0.0547	0.0945	CbGbCtD
Triazolam—CYP3A4—Topotecan—ovarian cancer	0.0448	0.0774	CbGbCtD
Triazolam—CYP3A5—Docetaxel—ovarian cancer	0.0412	0.0711	CbGbCtD
Triazolam—CYP2C9—Paclitaxel—ovarian cancer	0.0382	0.0659	CbGbCtD
Triazolam—CYP3A4—Vinorelbine—ovarian cancer	0.0316	0.0546	CbGbCtD
Triazolam—CYP3A4—Paclitaxel—ovarian cancer	0.0222	0.0383	CbGbCtD
Triazolam—CYP3A4—Docetaxel—ovarian cancer	0.0161	0.0277	CbGbCtD
Triazolam—CYP3A4—Doxorubicin—ovarian cancer	0.012	0.0207	CbGbCtD
Triazolam—TSPO—oviduct—ovarian cancer	0.00821	0.0868	CbGeAlD
Triazolam—GABRP—uterine cervix—ovarian cancer	0.00287	0.0303	CbGeAlD
Triazolam—GABRE—myometrium—ovarian cancer	0.00281	0.0297	CbGeAlD
Triazolam—GABRP—decidua—ovarian cancer	0.00273	0.0289	CbGeAlD
Triazolam—TSPO—myometrium—ovarian cancer	0.00263	0.0278	CbGeAlD
Triazolam—GABRP—endometrium—ovarian cancer	0.00259	0.0274	CbGeAlD
Triazolam—TSPO—embryo—ovarian cancer	0.00253	0.0267	CbGeAlD
Triazolam—GABRG3—testis—ovarian cancer	0.0025	0.0265	CbGeAlD
Triazolam—GABRP—uterus—ovarian cancer	0.00239	0.0253	CbGeAlD
Triazolam—GABRR1—testis—ovarian cancer	0.00239	0.0252	CbGeAlD
Triazolam—GABRE—uterine cervix—ovarian cancer	0.00219	0.0231	CbGeAlD
Triazolam—GABRB1—vagina—ovarian cancer	0.00217	0.0229	CbGeAlD
Triazolam—GABRP—female reproductive system—ovarian cancer	0.00215	0.0227	CbGeAlD
Triazolam—GABRE—decidua—ovarian cancer	0.00209	0.022	CbGeAlD
Triazolam—GABRD—testis—ovarian cancer	0.00207	0.0219	CbGeAlD
Triazolam—TSPO—epithelium—ovarian cancer	0.00206	0.0218	CbGeAlD
Triazolam—TSPO—uterine cervix—ovarian cancer	0.00204	0.0216	CbGeAlD
Triazolam—GABRE—endometrium—ovarian cancer	0.00198	0.0209	CbGeAlD
Triazolam—TSPO—decidua—ovarian cancer	0.00195	0.0206	CbGeAlD
Triazolam—GABRP—vagina—ovarian cancer	0.00194	0.0205	CbGeAlD
Triazolam—GABRA5—testis—ovarian cancer	0.00193	0.0204	CbGeAlD
Triazolam—TSPO—endometrium—ovarian cancer	0.00185	0.0195	CbGeAlD
Triazolam—GABRR2—lymph node—ovarian cancer	0.0018	0.019	CbGeAlD
Triazolam—GABRA3—testis—ovarian cancer	0.00179	0.0189	CbGeAlD
Triazolam—TSPO—gonad—ovarian cancer	0.00171	0.0181	CbGeAlD
Triazolam—TSPO—uterus—ovarian cancer	0.0017	0.018	CbGeAlD
Triazolam—GABRE—female reproductive system—ovarian cancer	0.00164	0.0173	CbGeAlD
Triazolam—GABRB3—gonad—ovarian cancer	0.00156	0.0165	CbGeAlD
Triazolam—TSPO—female reproductive system—ovarian cancer	0.00153	0.0162	CbGeAlD
Triazolam—GABRA2—vagina—ovarian cancer	0.0015	0.0158	CbGeAlD
Triazolam—GABRE—female gonad—ovarian cancer	0.00149	0.0158	CbGeAlD
Triazolam—GABRE—vagina—ovarian cancer	0.00148	0.0157	CbGeAlD
Triazolam—GABRB2—testis—ovarian cancer	0.00146	0.0154	CbGeAlD
Triazolam—TSPO—bone marrow—ovarian cancer	0.00145	0.0153	CbGeAlD
Triazolam—TSPO—female gonad—ovarian cancer	0.00139	0.0147	CbGeAlD
Triazolam—GABRB3—female reproductive system—ovarian cancer	0.00139	0.0147	CbGeAlD
Triazolam—TSPO—vagina—ovarian cancer	0.00139	0.0146	CbGeAlD
Triazolam—GABRE—testis—ovarian cancer	0.00132	0.014	CbGeAlD
Triazolam—CYP2C8—endometrium—ovarian cancer	0.00127	0.0134	CbGeAlD
Triazolam—CYP3A5—uterine cervix—ovarian cancer	0.00127	0.0134	CbGeAlD
Triazolam—TSPO—testis—ovarian cancer	0.00124	0.0131	CbGeAlD
Triazolam—GABRB3—testis—ovarian cancer	0.00112	0.0119	CbGeAlD
Triazolam—CYP2C8—female reproductive system—ovarian cancer	0.00105	0.0111	CbGeAlD
Triazolam—Paraesthesia—Melphalan—ovarian cancer	0.000988	0.00336	CcSEcCtD
Triazolam—Dyspnoea—Melphalan—ovarian cancer	0.000981	0.00334	CcSEcCtD
Triazolam—Decreased appetite—Topotecan—ovarian cancer	0.000977	0.00332	CcSEcCtD
Triazolam—Coordination abnormal—Doxorubicin—ovarian cancer	0.000977	0.00332	CcSEcCtD
Triazolam—Fatigue—Topotecan—ovarian cancer	0.000969	0.0033	CcSEcCtD
Triazolam—GABRA2—lymph node—ovarian cancer	0.000968	0.0102	CbGeAlD
Triazolam—Constipation—Topotecan—ovarian cancer	0.000961	0.00327	CcSEcCtD
Triazolam—Pain—Topotecan—ovarian cancer	0.000961	0.00327	CcSEcCtD
Triazolam—GABRE—lymph node—ovarian cancer	0.00096	0.0101	CbGeAlD
Triazolam—Decreased appetite—Melphalan—ovarian cancer	0.000957	0.00325	CcSEcCtD
Triazolam—CYP2C8—vagina—ovarian cancer	0.00095	0.01	CbGeAlD
Triazolam—Fatigue—Melphalan—ovarian cancer	0.000949	0.00323	CcSEcCtD
Triazolam—Pain—Melphalan—ovarian cancer	0.000941	0.0032	CcSEcCtD
Triazolam—Tachycardia—Vinorelbine—ovarian cancer	0.000939	0.00319	CcSEcCtD
Triazolam—CYP2C9—female reproductive system—ovarian cancer	0.000934	0.00987	CbGeAlD
Triazolam—Hypersensitivity—Chlorambucil—ovarian cancer	0.00093	0.00316	CcSEcCtD
Triazolam—Feeling abnormal—Topotecan—ovarian cancer	0.000926	0.00315	CcSEcCtD
Triazolam—Gastrointestinal pain—Topotecan—ovarian cancer	0.000919	0.00313	CcSEcCtD
Triazolam—Anorexia—Vinorelbine—ovarian cancer	0.000917	0.00312	CcSEcCtD
Triazolam—Asthenia—Chlorambucil—ovarian cancer	0.000906	0.00308	CcSEcCtD
Triazolam—Mental disability—Epirubicin—ovarian cancer	0.0009	0.00306	CcSEcCtD
Triazolam—TSPO—lymph node—ovarian cancer	0.000896	0.00947	CbGeAlD
Triazolam—Pruritus—Chlorambucil—ovarian cancer	0.000893	0.00304	CcSEcCtD
Triazolam—Abdominal pain—Topotecan—ovarian cancer	0.000889	0.00302	CcSEcCtD
Triazolam—Visual impairment—Paclitaxel—ovarian cancer	0.000877	0.00298	CcSEcCtD
Triazolam—Diarrhoea—Chlorambucil—ovarian cancer	0.000864	0.00294	CcSEcCtD
Triazolam—Paraesthesia—Vinorelbine—ovarian cancer	0.000864	0.00294	CcSEcCtD
Triazolam—CYP3A5—female gonad—ovarian cancer	0.000863	0.00912	CbGeAlD
Triazolam—CYP3A5—vagina—ovarian cancer	0.000858	0.00907	CbGeAlD
Triazolam—Dyspnoea—Vinorelbine—ovarian cancer	0.000857	0.00292	CcSEcCtD
Triazolam—Tinnitus—Paclitaxel—ovarian cancer	0.000849	0.00289	CcSEcCtD
Triazolam—CYP2C8—testis—ovarian cancer	0.000848	0.00896	CbGeAlD
Triazolam—Stomatitis—Docetaxel—ovarian cancer	0.000838	0.00285	CcSEcCtD
Triazolam—Jaundice—Docetaxel—ovarian cancer	0.000838	0.00285	CcSEcCtD
Triazolam—Hepatic failure—Epirubicin—ovarian cancer	0.000837	0.00285	CcSEcCtD
Triazolam—Decreased appetite—Vinorelbine—ovarian cancer	0.000836	0.00284	CcSEcCtD
Triazolam—Mental disability—Doxorubicin—ovarian cancer	0.000832	0.00283	CcSEcCtD
Triazolam—Fatigue—Vinorelbine—ovarian cancer	0.000829	0.00282	CcSEcCtD
Triazolam—Hypersensitivity—Topotecan—ovarian cancer	0.000828	0.00282	CcSEcCtD
Triazolam—Constipation—Vinorelbine—ovarian cancer	0.000822	0.0028	CcSEcCtD
Triazolam—Pain—Vinorelbine—ovarian cancer	0.000822	0.0028	CcSEcCtD
Triazolam—Hypersensitivity—Melphalan—ovarian cancer	0.000811	0.00276	CcSEcCtD
Triazolam—Asthenia—Topotecan—ovarian cancer	0.000807	0.00274	CcSEcCtD
Triazolam—Vomiting—Chlorambucil—ovarian cancer	0.000803	0.00273	CcSEcCtD
Triazolam—Pruritus—Topotecan—ovarian cancer	0.000795	0.0027	CcSEcCtD
Triazolam—Erythema—Paclitaxel—ovarian cancer	0.000793	0.0027	CcSEcCtD
Triazolam—Feeling abnormal—Vinorelbine—ovarian cancer	0.000793	0.00269	CcSEcCtD
Triazolam—Asthenia—Melphalan—ovarian cancer	0.00079	0.00269	CcSEcCtD
Triazolam—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000786	0.00267	CcSEcCtD
Triazolam—Flatulence—Paclitaxel—ovarian cancer	0.000781	0.00266	CcSEcCtD
Triazolam—Pruritus—Melphalan—ovarian cancer	0.000779	0.00265	CcSEcCtD
Triazolam—Tension—Paclitaxel—ovarian cancer	0.000778	0.00264	CcSEcCtD
Triazolam—Dysgeusia—Paclitaxel—ovarian cancer	0.000776	0.00264	CcSEcCtD
Triazolam—Hepatic failure—Doxorubicin—ovarian cancer	0.000775	0.00263	CcSEcCtD
Triazolam—Nervousness—Paclitaxel—ovarian cancer	0.00077	0.00262	CcSEcCtD
Triazolam—Diarrhoea—Topotecan—ovarian cancer	0.000769	0.00262	CcSEcCtD
Triazolam—Muscle spasms—Paclitaxel—ovarian cancer	0.000762	0.00259	CcSEcCtD
Triazolam—Abdominal pain—Vinorelbine—ovarian cancer	0.00076	0.00259	CcSEcCtD
Triazolam—Diarrhoea—Melphalan—ovarian cancer	0.000753	0.00256	CcSEcCtD
Triazolam—Osteoarthritis—Epirubicin—ovarian cancer	0.000752	0.00256	CcSEcCtD
Triazolam—Nausea—Chlorambucil—ovarian cancer	0.00075	0.00255	CcSEcCtD
Triazolam—Visual impairment—Docetaxel—ovarian cancer	0.000744	0.00253	CcSEcCtD
Triazolam—Dizziness—Topotecan—ovarian cancer	0.000743	0.00253	CcSEcCtD
Triazolam—Tremor—Paclitaxel—ovarian cancer	0.000743	0.00253	CcSEcCtD
Triazolam—Affect lability—Epirubicin—ovarian cancer	0.000741	0.00252	CcSEcCtD
Triazolam—Ill-defined disorder—Paclitaxel—ovarian cancer	0.000735	0.0025	CcSEcCtD
Triazolam—Agitation—Paclitaxel—ovarian cancer	0.000728	0.00248	CcSEcCtD
Triazolam—Vomiting—Topotecan—ovarian cancer	0.000715	0.00243	CcSEcCtD
Triazolam—Malaise—Paclitaxel—ovarian cancer	0.000715	0.00243	CcSEcCtD
Triazolam—Mood swings—Epirubicin—ovarian cancer	0.000713	0.00242	CcSEcCtD
Triazolam—CYP3A4—female reproductive system—ovarian cancer	0.000712	0.00752	CbGeAlD
Triazolam—Syncope—Paclitaxel—ovarian cancer	0.000711	0.00242	CcSEcCtD
Triazolam—Hypersensitivity—Vinorelbine—ovarian cancer	0.000709	0.00241	CcSEcCtD
Triazolam—Dermatitis—Topotecan—ovarian cancer	0.000708	0.00241	CcSEcCtD
Triazolam—Ataxia—Epirubicin—ovarian cancer	0.000708	0.00241	CcSEcCtD
Triazolam—Headache—Topotecan—ovarian cancer	0.000704	0.00239	CcSEcCtD
Triazolam—Palpitations—Paclitaxel—ovarian cancer	0.0007	0.00238	CcSEcCtD
Triazolam—Vomiting—Melphalan—ovarian cancer	0.0007	0.00238	CcSEcCtD
Triazolam—Loss of consciousness—Paclitaxel—ovarian cancer	0.000697	0.00237	CcSEcCtD
Triazolam—Osteoarthritis—Doxorubicin—ovarian cancer	0.000696	0.00237	CcSEcCtD
Triazolam—Dermatitis—Melphalan—ovarian cancer	0.000693	0.00236	CcSEcCtD
Triazolam—Asthenia—Vinorelbine—ovarian cancer	0.00069	0.00235	CcSEcCtD
Triazolam—Affect lability—Doxorubicin—ovarian cancer	0.000685	0.00233	CcSEcCtD
Triazolam—Hypertension—Paclitaxel—ovarian cancer	0.000684	0.00233	CcSEcCtD
Triazolam—Pruritus—Vinorelbine—ovarian cancer	0.00068	0.00231	CcSEcCtD
Triazolam—Chest pain—Paclitaxel—ovarian cancer	0.000675	0.00229	CcSEcCtD
Triazolam—Anxiety—Paclitaxel—ovarian cancer	0.000672	0.00229	CcSEcCtD
Triazolam—Erythema—Docetaxel—ovarian cancer	0.000672	0.00228	CcSEcCtD
Triazolam—Nausea—Topotecan—ovarian cancer	0.000668	0.00227	CcSEcCtD
Triazolam—Discomfort—Paclitaxel—ovarian cancer	0.000667	0.00227	CcSEcCtD
Triazolam—Muscular weakness—Epirubicin—ovarian cancer	0.000664	0.00226	CcSEcCtD
Triazolam—Dry mouth—Paclitaxel—ovarian cancer	0.00066	0.00224	CcSEcCtD
Triazolam—Mood swings—Doxorubicin—ovarian cancer	0.00066	0.00224	CcSEcCtD
Triazolam—Diarrhoea—Vinorelbine—ovarian cancer	0.000658	0.00224	CcSEcCtD
Triazolam—Dysgeusia—Docetaxel—ovarian cancer	0.000658	0.00224	CcSEcCtD
Triazolam—Ataxia—Doxorubicin—ovarian cancer	0.000655	0.00223	CcSEcCtD
Triazolam—Nausea—Melphalan—ovarian cancer	0.000654	0.00222	CcSEcCtD
Triazolam—Confusional state—Paclitaxel—ovarian cancer	0.000652	0.00222	CcSEcCtD
Triazolam—Oedema—Paclitaxel—ovarian cancer	0.000647	0.0022	CcSEcCtD
Triazolam—Muscle spasms—Docetaxel—ovarian cancer	0.000646	0.0022	CcSEcCtD
Triazolam—Shock—Paclitaxel—ovarian cancer	0.000636	0.00216	CcSEcCtD
Triazolam—Dizziness—Vinorelbine—ovarian cancer	0.000636	0.00216	CcSEcCtD
Triazolam—Tachycardia—Paclitaxel—ovarian cancer	0.000631	0.00215	CcSEcCtD
Triazolam—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000625	0.00213	CcSEcCtD
Triazolam—Anorexia—Paclitaxel—ovarian cancer	0.000617	0.0021	CcSEcCtD
Triazolam—Muscular weakness—Doxorubicin—ovarian cancer	0.000614	0.00209	CcSEcCtD
Triazolam—Vomiting—Vinorelbine—ovarian cancer	0.000611	0.00208	CcSEcCtD
Triazolam—Dysuria—Epirubicin—ovarian cancer	0.000608	0.00207	CcSEcCtD
Triazolam—Dermatitis—Vinorelbine—ovarian cancer	0.000606	0.00206	CcSEcCtD
Triazolam—Headache—Vinorelbine—ovarian cancer	0.000602	0.00205	CcSEcCtD
Triazolam—Syncope—Docetaxel—ovarian cancer	0.000602	0.00205	CcSEcCtD
Triazolam—Palpitations—Docetaxel—ovarian cancer	0.000594	0.00202	CcSEcCtD
Triazolam—Loss of consciousness—Docetaxel—ovarian cancer	0.00059	0.00201	CcSEcCtD
Triazolam—Insomnia—Paclitaxel—ovarian cancer	0.000585	0.00199	CcSEcCtD
Triazolam—Paraesthesia—Paclitaxel—ovarian cancer	0.000581	0.00198	CcSEcCtD
Triazolam—Hypertension—Docetaxel—ovarian cancer	0.00058	0.00197	CcSEcCtD
Triazolam—Drowsiness—Epirubicin—ovarian cancer	0.00058	0.00197	CcSEcCtD
Triazolam—Dyspnoea—Paclitaxel—ovarian cancer	0.000577	0.00196	CcSEcCtD
Triazolam—Somnolence—Paclitaxel—ovarian cancer	0.000575	0.00196	CcSEcCtD
Triazolam—Chest pain—Docetaxel—ovarian cancer	0.000572	0.00194	CcSEcCtD
Triazolam—Nausea—Vinorelbine—ovarian cancer	0.000571	0.00194	CcSEcCtD
Triazolam—Jaundice—Epirubicin—ovarian cancer	0.000565	0.00192	CcSEcCtD
Triazolam—Stomatitis—Epirubicin—ovarian cancer	0.000565	0.00192	CcSEcCtD
Triazolam—Dysuria—Doxorubicin—ovarian cancer	0.000563	0.00191	CcSEcCtD
Triazolam—Decreased appetite—Paclitaxel—ovarian cancer	0.000562	0.00191	CcSEcCtD
Triazolam—Dry mouth—Docetaxel—ovarian cancer	0.000559	0.0019	CcSEcCtD
Triazolam—Fatigue—Paclitaxel—ovarian cancer	0.000558	0.0019	CcSEcCtD
Triazolam—Pain—Paclitaxel—ovarian cancer	0.000553	0.00188	CcSEcCtD
Triazolam—Constipation—Paclitaxel—ovarian cancer	0.000553	0.00188	CcSEcCtD
Triazolam—Confusional state—Docetaxel—ovarian cancer	0.000553	0.00188	CcSEcCtD
Triazolam—Oedema—Docetaxel—ovarian cancer	0.000548	0.00186	CcSEcCtD
Triazolam—Shock—Docetaxel—ovarian cancer	0.000539	0.00183	CcSEcCtD
Triazolam—Drowsiness—Doxorubicin—ovarian cancer	0.000537	0.00182	CcSEcCtD
Triazolam—Tachycardia—Docetaxel—ovarian cancer	0.000535	0.00182	CcSEcCtD
Triazolam—Feeling abnormal—Paclitaxel—ovarian cancer	0.000533	0.00181	CcSEcCtD
Triazolam—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000529	0.0018	CcSEcCtD
Triazolam—Jaundice—Doxorubicin—ovarian cancer	0.000523	0.00178	CcSEcCtD
Triazolam—Stomatitis—Doxorubicin—ovarian cancer	0.000523	0.00178	CcSEcCtD
Triazolam—Anorexia—Docetaxel—ovarian cancer	0.000523	0.00178	CcSEcCtD
Triazolam—Abdominal pain—Paclitaxel—ovarian cancer	0.000511	0.00174	CcSEcCtD
Triazolam—Visual impairment—Epirubicin—ovarian cancer	0.000502	0.00171	CcSEcCtD
Triazolam—Insomnia—Docetaxel—ovarian cancer	0.000496	0.00169	CcSEcCtD
Triazolam—Paraesthesia—Docetaxel—ovarian cancer	0.000492	0.00167	CcSEcCtD
Triazolam—Dyspnoea—Docetaxel—ovarian cancer	0.000489	0.00166	CcSEcCtD
Triazolam—Somnolence—Docetaxel—ovarian cancer	0.000487	0.00166	CcSEcCtD
Triazolam—Tinnitus—Epirubicin—ovarian cancer	0.000485	0.00165	CcSEcCtD
Triazolam—Decreased appetite—Docetaxel—ovarian cancer	0.000477	0.00162	CcSEcCtD
Triazolam—Hypersensitivity—Paclitaxel—ovarian cancer	0.000477	0.00162	CcSEcCtD
Triazolam—Fatigue—Docetaxel—ovarian cancer	0.000473	0.00161	CcSEcCtD
Triazolam—Pain—Docetaxel—ovarian cancer	0.000469	0.00159	CcSEcCtD
Triazolam—Constipation—Docetaxel—ovarian cancer	0.000469	0.00159	CcSEcCtD
Triazolam—Visual impairment—Doxorubicin—ovarian cancer	0.000464	0.00158	CcSEcCtD
Triazolam—Asthenia—Paclitaxel—ovarian cancer	0.000464	0.00158	CcSEcCtD
Triazolam—Pruritus—Paclitaxel—ovarian cancer	0.000458	0.00156	CcSEcCtD
Triazolam—Erythema—Epirubicin—ovarian cancer	0.000453	0.00154	CcSEcCtD
Triazolam—Feeling abnormal—Docetaxel—ovarian cancer	0.000452	0.00154	CcSEcCtD
Triazolam—Tinnitus—Doxorubicin—ovarian cancer	0.000449	0.00153	CcSEcCtD
Triazolam—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000448	0.00152	CcSEcCtD
Triazolam—Flatulence—Epirubicin—ovarian cancer	0.000447	0.00152	CcSEcCtD
Triazolam—Tension—Epirubicin—ovarian cancer	0.000445	0.00151	CcSEcCtD
Triazolam—Dysgeusia—Epirubicin—ovarian cancer	0.000444	0.00151	CcSEcCtD
Triazolam—Diarrhoea—Paclitaxel—ovarian cancer	0.000443	0.00151	CcSEcCtD
Triazolam—Nervousness—Epirubicin—ovarian cancer	0.00044	0.0015	CcSEcCtD
Triazolam—Muscle spasms—Epirubicin—ovarian cancer	0.000436	0.00148	CcSEcCtD
Triazolam—Abdominal pain—Docetaxel—ovarian cancer	0.000433	0.00147	CcSEcCtD
Triazolam—Dizziness—Paclitaxel—ovarian cancer	0.000428	0.00145	CcSEcCtD
Triazolam—Ill-defined disorder—Epirubicin—ovarian cancer	0.00042	0.00143	CcSEcCtD
Triazolam—Erythema—Doxorubicin—ovarian cancer	0.000419	0.00143	CcSEcCtD
Triazolam—Agitation—Epirubicin—ovarian cancer	0.000416	0.00142	CcSEcCtD
Triazolam—Flatulence—Doxorubicin—ovarian cancer	0.000413	0.0014	CcSEcCtD
Triazolam—Tension—Doxorubicin—ovarian cancer	0.000411	0.0014	CcSEcCtD
Triazolam—Vomiting—Paclitaxel—ovarian cancer	0.000411	0.0014	CcSEcCtD
Triazolam—Dysgeusia—Doxorubicin—ovarian cancer	0.000411	0.0014	CcSEcCtD
Triazolam—Malaise—Epirubicin—ovarian cancer	0.000409	0.00139	CcSEcCtD
Triazolam—Dermatitis—Paclitaxel—ovarian cancer	0.000407	0.00139	CcSEcCtD
Triazolam—Nervousness—Doxorubicin—ovarian cancer	0.000407	0.00138	CcSEcCtD
Triazolam—Syncope—Epirubicin—ovarian cancer	0.000406	0.00138	CcSEcCtD
Triazolam—Headache—Paclitaxel—ovarian cancer	0.000405	0.00138	CcSEcCtD
Triazolam—Hypersensitivity—Docetaxel—ovarian cancer	0.000404	0.00137	CcSEcCtD
Triazolam—Muscle spasms—Doxorubicin—ovarian cancer	0.000403	0.00137	CcSEcCtD
Triazolam—Palpitations—Epirubicin—ovarian cancer	0.0004	0.00136	CcSEcCtD
Triazolam—Loss of consciousness—Epirubicin—ovarian cancer	0.000398	0.00135	CcSEcCtD
Triazolam—Asthenia—Docetaxel—ovarian cancer	0.000393	0.00134	CcSEcCtD
Triazolam—Hypertension—Epirubicin—ovarian cancer	0.000391	0.00133	CcSEcCtD
Triazolam—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000389	0.00132	CcSEcCtD
Triazolam—Pruritus—Docetaxel—ovarian cancer	0.000388	0.00132	CcSEcCtD
Triazolam—Chest pain—Epirubicin—ovarian cancer	0.000386	0.00131	CcSEcCtD
Triazolam—Agitation—Doxorubicin—ovarian cancer	0.000385	0.00131	CcSEcCtD
Triazolam—Anxiety—Epirubicin—ovarian cancer	0.000384	0.00131	CcSEcCtD
Triazolam—Nausea—Paclitaxel—ovarian cancer	0.000384	0.00131	CcSEcCtD
Triazolam—Discomfort—Epirubicin—ovarian cancer	0.000381	0.0013	CcSEcCtD
Triazolam—Malaise—Doxorubicin—ovarian cancer	0.000378	0.00129	CcSEcCtD
Triazolam—Dry mouth—Epirubicin—ovarian cancer	0.000377	0.00128	CcSEcCtD
Triazolam—Syncope—Doxorubicin—ovarian cancer	0.000376	0.00128	CcSEcCtD
Triazolam—Diarrhoea—Docetaxel—ovarian cancer	0.000375	0.00128	CcSEcCtD
Triazolam—Confusional state—Epirubicin—ovarian cancer	0.000373	0.00127	CcSEcCtD
Triazolam—Palpitations—Doxorubicin—ovarian cancer	0.000371	0.00126	CcSEcCtD
Triazolam—Oedema—Epirubicin—ovarian cancer	0.00037	0.00126	CcSEcCtD
Triazolam—Loss of consciousness—Doxorubicin—ovarian cancer	0.000369	0.00125	CcSEcCtD
Triazolam—Shock—Epirubicin—ovarian cancer	0.000364	0.00124	CcSEcCtD
Triazolam—Dizziness—Docetaxel—ovarian cancer	0.000363	0.00123	CcSEcCtD
Triazolam—Hypertension—Doxorubicin—ovarian cancer	0.000362	0.00123	CcSEcCtD
Triazolam—Tachycardia—Epirubicin—ovarian cancer	0.000361	0.00123	CcSEcCtD
Triazolam—Hyperhidrosis—Epirubicin—ovarian cancer	0.000358	0.00122	CcSEcCtD
Triazolam—Chest pain—Doxorubicin—ovarian cancer	0.000357	0.00121	CcSEcCtD
Triazolam—Anxiety—Doxorubicin—ovarian cancer	0.000356	0.00121	CcSEcCtD
Triazolam—Discomfort—Doxorubicin—ovarian cancer	0.000353	0.0012	CcSEcCtD
Triazolam—Anorexia—Epirubicin—ovarian cancer	0.000353	0.0012	CcSEcCtD
Triazolam—Dry mouth—Doxorubicin—ovarian cancer	0.000349	0.00119	CcSEcCtD
Triazolam—Vomiting—Docetaxel—ovarian cancer	0.000349	0.00119	CcSEcCtD
Triazolam—Dermatitis—Docetaxel—ovarian cancer	0.000345	0.00117	CcSEcCtD
Triazolam—Confusional state—Doxorubicin—ovarian cancer	0.000345	0.00117	CcSEcCtD
Triazolam—Headache—Docetaxel—ovarian cancer	0.000343	0.00117	CcSEcCtD
Triazolam—Oedema—Doxorubicin—ovarian cancer	0.000342	0.00116	CcSEcCtD
Triazolam—Shock—Doxorubicin—ovarian cancer	0.000337	0.00114	CcSEcCtD
Triazolam—Insomnia—Epirubicin—ovarian cancer	0.000334	0.00114	CcSEcCtD
Triazolam—Tachycardia—Doxorubicin—ovarian cancer	0.000334	0.00114	CcSEcCtD
Triazolam—Paraesthesia—Epirubicin—ovarian cancer	0.000332	0.00113	CcSEcCtD
Triazolam—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000331	0.00112	CcSEcCtD
Triazolam—Dyspnoea—Epirubicin—ovarian cancer	0.00033	0.00112	CcSEcCtD
Triazolam—Somnolence—Epirubicin—ovarian cancer	0.000329	0.00112	CcSEcCtD
Triazolam—Anorexia—Doxorubicin—ovarian cancer	0.000326	0.00111	CcSEcCtD
Triazolam—Nausea—Docetaxel—ovarian cancer	0.000326	0.00111	CcSEcCtD
Triazolam—Decreased appetite—Epirubicin—ovarian cancer	0.000321	0.00109	CcSEcCtD
Triazolam—Fatigue—Epirubicin—ovarian cancer	0.000319	0.00108	CcSEcCtD
Triazolam—Constipation—Epirubicin—ovarian cancer	0.000316	0.00108	CcSEcCtD
Triazolam—Pain—Epirubicin—ovarian cancer	0.000316	0.00108	CcSEcCtD
Triazolam—Insomnia—Doxorubicin—ovarian cancer	0.000309	0.00105	CcSEcCtD
Triazolam—Paraesthesia—Doxorubicin—ovarian cancer	0.000307	0.00104	CcSEcCtD
Triazolam—Dyspnoea—Doxorubicin—ovarian cancer	0.000305	0.00104	CcSEcCtD
Triazolam—Feeling abnormal—Epirubicin—ovarian cancer	0.000305	0.00104	CcSEcCtD
Triazolam—Somnolence—Doxorubicin—ovarian cancer	0.000304	0.00103	CcSEcCtD
Triazolam—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000302	0.00103	CcSEcCtD
Triazolam—Decreased appetite—Doxorubicin—ovarian cancer	0.000297	0.00101	CcSEcCtD
Triazolam—Fatigue—Doxorubicin—ovarian cancer	0.000295	0.001	CcSEcCtD
Triazolam—Pain—Doxorubicin—ovarian cancer	0.000293	0.000995	CcSEcCtD
Triazolam—Constipation—Doxorubicin—ovarian cancer	0.000293	0.000995	CcSEcCtD
Triazolam—Abdominal pain—Epirubicin—ovarian cancer	0.000292	0.000994	CcSEcCtD
Triazolam—Feeling abnormal—Doxorubicin—ovarian cancer	0.000282	0.000959	CcSEcCtD
Triazolam—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.00028	0.000951	CcSEcCtD
Triazolam—Hypersensitivity—Epirubicin—ovarian cancer	0.000272	0.000927	CcSEcCtD
Triazolam—Abdominal pain—Doxorubicin—ovarian cancer	0.000271	0.00092	CcSEcCtD
Triazolam—Asthenia—Epirubicin—ovarian cancer	0.000265	0.000902	CcSEcCtD
Triazolam—Pruritus—Epirubicin—ovarian cancer	0.000262	0.00089	CcSEcCtD
Triazolam—Diarrhoea—Epirubicin—ovarian cancer	0.000253	0.00086	CcSEcCtD
Triazolam—Hypersensitivity—Doxorubicin—ovarian cancer	0.000252	0.000857	CcSEcCtD
Triazolam—Asthenia—Doxorubicin—ovarian cancer	0.000246	0.000835	CcSEcCtD
Triazolam—Dizziness—Epirubicin—ovarian cancer	0.000245	0.000832	CcSEcCtD
Triazolam—Pruritus—Doxorubicin—ovarian cancer	0.000242	0.000823	CcSEcCtD
Triazolam—Vomiting—Epirubicin—ovarian cancer	0.000235	0.0008	CcSEcCtD
Triazolam—Diarrhoea—Doxorubicin—ovarian cancer	0.000234	0.000796	CcSEcCtD
Triazolam—Dermatitis—Epirubicin—ovarian cancer	0.000233	0.000792	CcSEcCtD
Triazolam—Headache—Epirubicin—ovarian cancer	0.000232	0.000788	CcSEcCtD
Triazolam—Dizziness—Doxorubicin—ovarian cancer	0.000226	0.000769	CcSEcCtD
Triazolam—Nausea—Epirubicin—ovarian cancer	0.00022	0.000747	CcSEcCtD
Triazolam—Vomiting—Doxorubicin—ovarian cancer	0.000218	0.00074	CcSEcCtD
Triazolam—Dermatitis—Doxorubicin—ovarian cancer	0.000216	0.000733	CcSEcCtD
Triazolam—Headache—Doxorubicin—ovarian cancer	0.000214	0.000729	CcSEcCtD
Triazolam—Nausea—Doxorubicin—ovarian cancer	0.000203	0.000691	CcSEcCtD
Triazolam—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	4.57e-05	0.00142	CbGpPWpGaD
Triazolam—GABRB1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	4.53e-05	0.00141	CbGpPWpGaD
Triazolam—CYP2C8—Biological oxidations—CYP1B1—ovarian cancer	4.52e-05	0.00141	CbGpPWpGaD
Triazolam—GABRR1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	4.49e-05	0.0014	CbGpPWpGaD
Triazolam—GABRR1—Transmembrane transport of small molecules—ABCB1—ovarian cancer	4.46e-05	0.00139	CbGpPWpGaD
Triazolam—CYP2C8—Metapathway biotransformation—CYP1B1—ovarian cancer	4.46e-05	0.00139	CbGpPWpGaD
Triazolam—GABRG3—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	4.44e-05	0.00138	CbGpPWpGaD
Triazolam—GABRB3—BDNF signaling pathway—CASP3—ovarian cancer	4.41e-05	0.00137	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—NME2—ovarian cancer	4.4e-05	0.00137	CbGpPWpGaD
Triazolam—GABRG3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	4.39e-05	0.00137	CbGpPWpGaD
Triazolam—GABRB1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	4.38e-05	0.00136	CbGpPWpGaD
Triazolam—GABRB1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	4.33e-05	0.00135	CbGpPWpGaD
Triazolam—GABRA6—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	4.29e-05	0.00133	CbGpPWpGaD
Triazolam—GABRQ—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	4.28e-05	0.00133	CbGpPWpGaD
Triazolam—GABRR2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	4.28e-05	0.00133	CbGpPWpGaD
Triazolam—GABRR2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	4.26e-05	0.00133	CbGpPWpGaD
Triazolam—GABRQ—Transmembrane transport of small molecules—ABCB1—ovarian cancer	4.26e-05	0.00133	CbGpPWpGaD
Triazolam—GABRB3—BDNF signaling pathway—CTNNB1—ovarian cancer	4.25e-05	0.00132	CbGpPWpGaD
Triazolam—GABRA4—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	4.23e-05	0.00132	CbGpPWpGaD
Triazolam—GABRR1—Transmission across Chemical Synapses—MAPK1—ovarian cancer	4.21e-05	0.00131	CbGpPWpGaD
Triazolam—GABRA6—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	4.14e-05	0.00129	CbGpPWpGaD
Triazolam—GABRA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	4.1e-05	0.00127	CbGpPWpGaD
Triazolam—GABRA4—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	4.09e-05	0.00127	CbGpPWpGaD
Triazolam—GABRA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	4.04e-05	0.00126	CbGpPWpGaD
Triazolam—GABRQ—Transmission across Chemical Synapses—MAPK1—ovarian cancer	4.01e-05	0.00125	CbGpPWpGaD
Triazolam—GABRR2—Transmission across Chemical Synapses—MAPK1—ovarian cancer	4.01e-05	0.00125	CbGpPWpGaD
Triazolam—GABRB2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	3.87e-05	0.0012	CbGpPWpGaD
Triazolam—GABRA5—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	3.76e-05	0.00117	CbGpPWpGaD
Triazolam—GABRB2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	3.74e-05	0.00116	CbGpPWpGaD
Triazolam—GABRA1—SIDS Susceptibility Pathways—CXCL8—ovarian cancer	3.71e-05	0.00115	CbGpPWpGaD
Triazolam—GABRB3—BDNF signaling pathway—STAT3—ovarian cancer	3.71e-05	0.00115	CbGpPWpGaD
Triazolam—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	3.7e-05	0.00115	CbGpPWpGaD
Triazolam—GABRA3—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	3.69e-05	0.00115	CbGpPWpGaD
Triazolam—CYP2C9—Biological oxidations—CYP1B1—ovarian cancer	3.68e-05	0.00114	CbGpPWpGaD
Triazolam—GABRA5—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	3.63e-05	0.00113	CbGpPWpGaD
Triazolam—GABRA2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	3.63e-05	0.00113	CbGpPWpGaD
Triazolam—CYP2C9—Metapathway biotransformation—CYP1B1—ovarian cancer	3.63e-05	0.00113	CbGpPWpGaD
Triazolam—GABRB3—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	3.61e-05	0.00112	CbGpPWpGaD
Triazolam—GABRA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	3.59e-05	0.00112	CbGpPWpGaD
Triazolam—GABRA3—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	3.57e-05	0.00111	CbGpPWpGaD
Triazolam—GABRA1—SIDS Susceptibility Pathways—CASP3—ovarian cancer	3.55e-05	0.0011	CbGpPWpGaD
Triazolam—GABRG2—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	3.54e-05	0.0011	CbGpPWpGaD
Triazolam—GABRB3—BDNF signaling pathway—MAPK3—ovarian cancer	3.54e-05	0.0011	CbGpPWpGaD
Triazolam—GABRA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	3.53e-05	0.0011	CbGpPWpGaD
Triazolam—GABRG3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	3.53e-05	0.0011	CbGpPWpGaD
Triazolam—GABRG3—Transmembrane transport of small molecules—ABCB1—ovarian cancer	3.51e-05	0.00109	CbGpPWpGaD
Triazolam—GABRA2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	3.51e-05	0.00109	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	3.48e-05	0.00108	CbGpPWpGaD
Triazolam—GABRB3—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	3.48e-05	0.00108	CbGpPWpGaD
Triazolam—GABRB1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	3.48e-05	0.00108	CbGpPWpGaD
Triazolam—GABRA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	3.47e-05	0.00108	CbGpPWpGaD
Triazolam—GABRB1—Transmembrane transport of small molecules—ABCB1—ovarian cancer	3.45e-05	0.00107	CbGpPWpGaD
Triazolam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	3.45e-05	0.00107	CbGpPWpGaD
Triazolam—GABRA1—SIDS Susceptibility Pathways—CTNNB1—ovarian cancer	3.42e-05	0.00106	CbGpPWpGaD
Triazolam—GABRG2—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	3.42e-05	0.00106	CbGpPWpGaD
Triazolam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	3.38e-05	0.00105	CbGpPWpGaD
Triazolam—GABRR1—Transmission across Chemical Synapses—HRAS—ovarian cancer	3.38e-05	0.00105	CbGpPWpGaD
Triazolam—GABRB3—BDNF signaling pathway—MAPK1—ovarian cancer	3.37e-05	0.00105	CbGpPWpGaD
Triazolam—GABRG3—Transmission across Chemical Synapses—MAPK1—ovarian cancer	3.3e-05	0.00103	CbGpPWpGaD
Triazolam—GABRA6—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	3.29e-05	0.00102	CbGpPWpGaD
Triazolam—GABRA6—Transmembrane transport of small molecules—ABCB1—ovarian cancer	3.27e-05	0.00102	CbGpPWpGaD
Triazolam—GABRB1—Transmission across Chemical Synapses—MAPK1—ovarian cancer	3.25e-05	0.00101	CbGpPWpGaD
Triazolam—GABRA4—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	3.25e-05	0.00101	CbGpPWpGaD
Triazolam—GABRA4—Transmembrane transport of small molecules—ABCB1—ovarian cancer	3.23e-05	0.001	CbGpPWpGaD
Triazolam—GABRR1—Neuronal System—MAPK1—ovarian cancer	3.22e-05	0.001	CbGpPWpGaD
Triazolam—GABRR2—Transmission across Chemical Synapses—HRAS—ovarian cancer	3.22e-05	0.001	CbGpPWpGaD
Triazolam—GABRQ—Transmission across Chemical Synapses—HRAS—ovarian cancer	3.22e-05	0.001	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—NME2—ovarian cancer	3.18e-05	0.00099	CbGpPWpGaD
Triazolam—GABRA1—Transmembrane transport of small molecules—SLC5A5—ovarian cancer	3.1e-05	0.000963	CbGpPWpGaD
Triazolam—GABRA6—Transmission across Chemical Synapses—MAPK1—ovarian cancer	3.08e-05	0.000958	CbGpPWpGaD
Triazolam—GABRR2—Neuronal System—MAPK1—ovarian cancer	3.07e-05	0.000956	CbGpPWpGaD
Triazolam—GABRQ—Neuronal System—MAPK1—ovarian cancer	3.07e-05	0.000956	CbGpPWpGaD
Triazolam—GABRA4—Transmission across Chemical Synapses—MAPK1—ovarian cancer	3.04e-05	0.000946	CbGpPWpGaD
Triazolam—GABRA1—SIDS Susceptibility Pathways—VEGFA—ovarian cancer	3.01e-05	0.000937	CbGpPWpGaD
Triazolam—GABRA1—Transmembrane transport of small molecules—SLC2A1—ovarian cancer	2.99e-05	0.00093	CbGpPWpGaD
Triazolam—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	2.97e-05	0.000924	CbGpPWpGaD
Triazolam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—ovarian cancer	2.96e-05	0.00092	CbGpPWpGaD
Triazolam—GABRB2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	2.95e-05	0.000919	CbGpPWpGaD
Triazolam—GABRA5—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	2.89e-05	0.000898	CbGpPWpGaD
Triazolam—GABRA5—Transmembrane transport of small molecules—ABCB1—ovarian cancer	2.87e-05	0.000892	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	2.84e-05	0.000882	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—CYTB—ovarian cancer	2.84e-05	0.000882	CbGpPWpGaD
Triazolam—GABRA3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	2.83e-05	0.000881	CbGpPWpGaD
Triazolam—GABRA3—Transmembrane transport of small molecules—ABCB1—ovarian cancer	2.82e-05	0.000876	CbGpPWpGaD
Triazolam—GABRA2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	2.78e-05	0.000866	CbGpPWpGaD
Triazolam—GABRB2—Transmission across Chemical Synapses—MAPK1—ovarian cancer	2.78e-05	0.000865	CbGpPWpGaD
Triazolam—GABRA2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	2.77e-05	0.000861	CbGpPWpGaD
Triazolam—GABRB3—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	2.77e-05	0.000861	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—NME2—ovarian cancer	2.76e-05	0.000857	CbGpPWpGaD
Triazolam—GABRB3—Transmembrane transport of small molecules—ABCB1—ovarian cancer	2.75e-05	0.000856	CbGpPWpGaD
Triazolam—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	2.72e-05	0.000845	CbGpPWpGaD
Triazolam—GABRB3—BDNF signaling pathway—HRAS—ovarian cancer	2.7e-05	0.000841	CbGpPWpGaD
Triazolam—GABRA5—Transmission across Chemical Synapses—MAPK1—ovarian cancer	2.7e-05	0.000841	CbGpPWpGaD
Triazolam—GABRG2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	2.7e-05	0.00084	CbGpPWpGaD
Triazolam—GABRA3—Transmission across Chemical Synapses—MAPK1—ovarian cancer	2.65e-05	0.000825	CbGpPWpGaD
Triazolam—GABRG3—Transmission across Chemical Synapses—HRAS—ovarian cancer	2.65e-05	0.000825	CbGpPWpGaD
Triazolam—GABRB1—Transmission across Chemical Synapses—HRAS—ovarian cancer	2.61e-05	0.000813	CbGpPWpGaD
Triazolam—GABRA2—Transmission across Chemical Synapses—MAPK1—ovarian cancer	2.61e-05	0.000811	CbGpPWpGaD
Triazolam—GABRB3—Transmission across Chemical Synapses—MAPK1—ovarian cancer	2.59e-05	0.000806	CbGpPWpGaD
Triazolam—GABRR1—Neuronal System—HRAS—ovarian cancer	2.59e-05	0.000805	CbGpPWpGaD
Triazolam—GABRG2—Transmission across Chemical Synapses—MAPK1—ovarian cancer	2.54e-05	0.000791	CbGpPWpGaD
Triazolam—GABRG3—Neuronal System—MAPK1—ovarian cancer	2.53e-05	0.000788	CbGpPWpGaD
Triazolam—GABRB1—Neuronal System—MAPK1—ovarian cancer	2.49e-05	0.000776	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—BRIP1—ovarian cancer	2.48e-05	0.000771	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—PPP1CC—ovarian cancer	2.48e-05	0.000771	CbGpPWpGaD
Triazolam—GABRA6—Transmission across Chemical Synapses—HRAS—ovarian cancer	2.47e-05	0.000769	CbGpPWpGaD
Triazolam—GABRR2—Neuronal System—HRAS—ovarian cancer	2.47e-05	0.000768	CbGpPWpGaD
Triazolam—GABRQ—Neuronal System—HRAS—ovarian cancer	2.47e-05	0.000768	CbGpPWpGaD
Triazolam—GABRA4—Transmission across Chemical Synapses—HRAS—ovarian cancer	2.44e-05	0.000759	CbGpPWpGaD
Triazolam—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	2.43e-05	0.000755	CbGpPWpGaD
Triazolam—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	2.39e-05	0.000744	CbGpPWpGaD
Triazolam—GABRB3—BDNF signaling pathway—AKT1—ovarian cancer	2.39e-05	0.000743	CbGpPWpGaD
Triazolam—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—ovarian cancer	2.37e-05	0.000739	CbGpPWpGaD
Triazolam—GABRA1—Transmembrane transport of small molecules—ABCB1—ovarian cancer	2.36e-05	0.000734	CbGpPWpGaD
Triazolam—GABRA6—Neuronal System—MAPK1—ovarian cancer	2.36e-05	0.000734	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	2.34e-05	0.000727	CbGpPWpGaD
Triazolam—GABRA4—Neuronal System—MAPK1—ovarian cancer	2.33e-05	0.000725	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—NME2—ovarian cancer	2.24e-05	0.000698	CbGpPWpGaD
Triazolam—GABRB2—Transmission across Chemical Synapses—HRAS—ovarian cancer	2.23e-05	0.000695	CbGpPWpGaD
Triazolam—GABRA1—Transmission across Chemical Synapses—MAPK1—ovarian cancer	2.22e-05	0.000692	CbGpPWpGaD
Triazolam—GABRA5—Transmission across Chemical Synapses—HRAS—ovarian cancer	2.17e-05	0.000675	CbGpPWpGaD
Triazolam—GABRB2—Neuronal System—MAPK1—ovarian cancer	2.13e-05	0.000663	CbGpPWpGaD
Triazolam—GABRA3—Transmission across Chemical Synapses—HRAS—ovarian cancer	2.13e-05	0.000663	CbGpPWpGaD
Triazolam—GABRA2—Transmission across Chemical Synapses—HRAS—ovarian cancer	2.09e-05	0.000651	CbGpPWpGaD
Triazolam—GABRA1—SIDS Susceptibility Pathways—IL6—ovarian cancer	2.08e-05	0.000648	CbGpPWpGaD
Triazolam—GABRB3—Transmission across Chemical Synapses—HRAS—ovarian cancer	2.08e-05	0.000647	CbGpPWpGaD
Triazolam—GABRA5—Neuronal System—MAPK1—ovarian cancer	2.07e-05	0.000644	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—CYTB—ovarian cancer	2.05e-05	0.000638	CbGpPWpGaD
Triazolam—GABRG2—Transmission across Chemical Synapses—HRAS—ovarian cancer	2.04e-05	0.000635	CbGpPWpGaD
Triazolam—GABRA3—Neuronal System—MAPK1—ovarian cancer	2.03e-05	0.000632	CbGpPWpGaD
Triazolam—GABRG3—Neuronal System—HRAS—ovarian cancer	2.03e-05	0.000632	CbGpPWpGaD
Triazolam—GABRB1—Neuronal System—HRAS—ovarian cancer	2e-05	0.000623	CbGpPWpGaD
Triazolam—GABRA2—Neuronal System—MAPK1—ovarian cancer	2e-05	0.000622	CbGpPWpGaD
Triazolam—GABRB3—Neuronal System—MAPK1—ovarian cancer	1.98e-05	0.000617	CbGpPWpGaD
Triazolam—GABRG2—Neuronal System—MAPK1—ovarian cancer	1.95e-05	0.000606	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	1.91e-05	0.000593	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	1.9e-05	0.000592	CbGpPWpGaD
Triazolam—GABRA6—Neuronal System—HRAS—ovarian cancer	1.89e-05	0.000589	CbGpPWpGaD
Triazolam—GABRA4—Neuronal System—HRAS—ovarian cancer	1.87e-05	0.000582	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—BRIP1—ovarian cancer	1.79e-05	0.000557	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—PPP1CC—ovarian cancer	1.79e-05	0.000557	CbGpPWpGaD
Triazolam—GABRA1—Transmission across Chemical Synapses—HRAS—ovarian cancer	1.78e-05	0.000555	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—CYTB—ovarian cancer	1.78e-05	0.000552	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	1.74e-05	0.00054	CbGpPWpGaD
Triazolam—GABRB2—Neuronal System—HRAS—ovarian cancer	1.71e-05	0.000532	CbGpPWpGaD
Triazolam—GABRA1—Neuronal System—MAPK1—ovarian cancer	1.7e-05	0.00053	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—YAP1—ovarian cancer	1.66e-05	0.000517	CbGpPWpGaD
Triazolam—GABRA5—Neuronal System—HRAS—ovarian cancer	1.66e-05	0.000517	CbGpPWpGaD
Triazolam—GABRA3—Neuronal System—HRAS—ovarian cancer	1.63e-05	0.000508	CbGpPWpGaD
Triazolam—GABRA2—Neuronal System—HRAS—ovarian cancer	1.6e-05	0.000499	CbGpPWpGaD
Triazolam—GABRB3—Neuronal System—HRAS—ovarian cancer	1.59e-05	0.000496	CbGpPWpGaD
Triazolam—GABRG2—Neuronal System—HRAS—ovarian cancer	1.56e-05	0.000487	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—PPP1CC—ovarian cancer	1.55e-05	0.000483	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—BRIP1—ovarian cancer	1.55e-05	0.000483	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	1.55e-05	0.000482	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—NME2—ovarian cancer	1.48e-05	0.00046	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—CYTB—ovarian cancer	1.45e-05	0.00045	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	1.41e-05	0.000439	CbGpPWpGaD
Triazolam—GABRA1—Neuronal System—HRAS—ovarian cancer	1.37e-05	0.000425	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—FASN—ovarian cancer	1.36e-05	0.000422	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—SLC5A5—ovarian cancer	1.33e-05	0.000415	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—SLC2A1—ovarian cancer	1.29e-05	0.000401	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—PPP1CC—ovarian cancer	1.26e-05	0.000393	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—BRIP1—ovarian cancer	1.26e-05	0.000393	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—CYP1B1—ovarian cancer	1.23e-05	0.000384	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—YAP1—ovarian cancer	1.2e-05	0.000374	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.13e-05	0.000352	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—PPP2R1A—ovarian cancer	1.09e-05	0.000341	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—YAP1—ovarian cancer	1.04e-05	0.000324	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.03e-05	0.000321	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—ABCB1—ovarian cancer	1.02e-05	0.000316	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—TYMS—ovarian cancer	9.98e-06	0.000311	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—FASN—ovarian cancer	9.8e-06	0.000305	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—SLC5A5—ovarian cancer	9.64e-06	0.0003	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—CYTB—ovarian cancer	9.53e-06	0.000297	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—SLC2A1—ovarian cancer	9.31e-06	0.00029	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	9.2e-06	0.000286	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	9.06e-06	0.000282	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—CYP1B1—ovarian cancer	8.92e-06	0.000278	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—FASN—ovarian cancer	8.49e-06	0.000264	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—YAP1—ovarian cancer	8.47e-06	0.000264	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	8.38e-06	0.000261	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—SLC5A5—ovarian cancer	8.35e-06	0.00026	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—PPP1CC—ovarian cancer	8.33e-06	0.000259	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—BRIP1—ovarian cancer	8.33e-06	0.000259	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—SLC2A1—ovarian cancer	8.06e-06	0.000251	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—CAV1—ovarian cancer	8.04e-06	0.00025	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—PPP2R1A—ovarian cancer	7.91e-06	0.000246	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	7.89e-06	0.000246	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—CYP1B1—ovarian cancer	7.73e-06	0.00024	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	7.37e-06	0.000229	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—ABCB1—ovarian cancer	7.35e-06	0.000229	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—PIK3CG—ovarian cancer	7.33e-06	0.000228	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—TYMS—ovarian cancer	7.22e-06	0.000225	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—FASN—ovarian cancer	6.91e-06	0.000215	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—PPP2R1A—ovarian cancer	6.85e-06	0.000213	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	6.82e-06	0.000212	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—SLC5A5—ovarian cancer	6.79e-06	0.000211	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—SLC2A1—ovarian cancer	6.56e-06	0.000204	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—PIK3CD—ovarian cancer	6.44e-06	0.0002	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	6.42e-06	0.0002	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—ABCB1—ovarian cancer	6.36e-06	0.000198	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—CYP1B1—ovarian cancer	6.29e-06	0.000196	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—TYMS—ovarian cancer	6.25e-06	0.000194	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—CAV1—ovarian cancer	5.81e-06	0.000181	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—PIK3CB—ovarian cancer	5.61e-06	0.000175	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—YAP1—ovarian cancer	5.59e-06	0.000174	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	5.58e-06	0.000174	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	5.55e-06	0.000173	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—PIK3CG—ovarian cancer	5.3e-06	0.000165	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—ABCB1—ovarian cancer	5.18e-06	0.000161	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—TYMS—ovarian cancer	5.09e-06	0.000158	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—CAV1—ovarian cancer	5.04e-06	0.000157	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—PTEN—ovarian cancer	4.85e-06	0.000151	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.81e-06	0.00015	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—PIK3CD—ovarian cancer	4.66e-06	0.000145	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—PIK3CG—ovarian cancer	4.59e-06	0.000143	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—FASN—ovarian cancer	4.55e-06	0.000142	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—SLC5A5—ovarian cancer	4.48e-06	0.000139	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—SLC2A1—ovarian cancer	4.33e-06	0.000135	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—CYP1B1—ovarian cancer	4.15e-06	0.000129	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—CAV1—ovarian cancer	4.1e-06	0.000128	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—PIK3CB—ovarian cancer	4.06e-06	0.000126	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—PIK3CD—ovarian cancer	4.03e-06	0.000125	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	3.92e-06	0.000122	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—PIK3CG—ovarian cancer	3.73e-06	0.000116	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	3.68e-06	0.000114	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—PIK3CB—ovarian cancer	3.52e-06	0.000109	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—PTEN—ovarian cancer	3.51e-06	0.000109	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—PIK3CA—ovarian cancer	3.42e-06	0.000106	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—ABCB1—ovarian cancer	3.42e-06	0.000106	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—TYMS—ovarian cancer	3.35e-06	0.000104	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—PIK3CD—ovarian cancer	3.28e-06	0.000102	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—PTEN—ovarian cancer	3.04e-06	9.45e-05	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—PIK3CB—ovarian cancer	2.86e-06	8.9e-05	CbGpPWpGaD
Triazolam—CYP3A7—Metabolism—AKT1—ovarian cancer	2.8e-06	8.7e-05	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—CAV1—ovarian cancer	2.7e-06	8.41e-05	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—PIK3CA—ovarian cancer	2.47e-06	7.7e-05	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—PTEN—ovarian cancer	2.47e-06	7.69e-05	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—PIK3CG—ovarian cancer	2.46e-06	7.66e-05	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—PIK3CD—ovarian cancer	2.16e-06	6.74e-05	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—PIK3CA—ovarian cancer	2.14e-06	6.67e-05	CbGpPWpGaD
Triazolam—CYP3A5—Metabolism—AKT1—ovarian cancer	2.02e-06	6.29e-05	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—PIK3CB—ovarian cancer	1.89e-06	5.87e-05	CbGpPWpGaD
Triazolam—CYP2C8—Metabolism—AKT1—ovarian cancer	1.75e-06	5.45e-05	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—PIK3CA—ovarian cancer	1.74e-06	5.43e-05	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—PTEN—ovarian cancer	1.63e-06	5.07e-05	CbGpPWpGaD
Triazolam—CYP2C9—Metabolism—AKT1—ovarian cancer	1.42e-06	4.43e-05	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.15e-06	3.58e-05	CbGpPWpGaD
Triazolam—CYP3A4—Metabolism—AKT1—ovarian cancer	9.4e-07	2.92e-05	CbGpPWpGaD
